JP Morgan Downgrades Dyne Therapeutics to Neutral, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero has downgraded Dyne Therapeutics from Overweight to Neutral and reduced the price target from $43 to $35.
October 24, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan has downgraded Dyne Therapeutics from Overweight to Neutral, with a reduced price target of $35, indicating a less optimistic outlook.
The downgrade from Overweight to Neutral by a major financial institution like JP Morgan suggests a less favorable view on Dyne Therapeutics' stock, which is likely to lead to short-term selling pressure. The lowered price target from $43 to $35 further supports this negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100